Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 May;53(5):1211-4.
doi: 10.1007/s10620-007-0016-x. Epub 2007 Oct 16.

Helicobacter pylori recurrence and infection rate in Israeli adults

Affiliations

Helicobacter pylori recurrence and infection rate in Israeli adults

Yaron Niv et al. Dig Dis Sci. 2008 May.

Abstract

Introduction: In developing countries the recurrence rate of Helicobacter pylori after successful eradication therapy is as high as 42%, while in developed countries it is estimated to be less than 3%. Such figures are very important in terms of determining clinical strategy and outcome.

Aim: To estimate the recurrence rate of H. pylori in Israel using the database of the "Central H. Pylori Laboratory of Clalit Health Services".

Methods: The database was searched for patients who had undergone the [(13)C]-urea breath test ([(13)C]-UBT) for validation of the successful eradication of H. pylori or for evaluation of dyspepsia 7 years previously and for whom the result had been negative. These patients were invited to participate in the trial, fill a symptom questionnaire and undergo another [(13)C]-UBT.

Results: A In total, 65 patients participated; of these, 26 patients had tested negative in the first( 13)CUBT, indicating the successful eradication of H. pylori (Group A), and 39 had been tested for dyspepsia (Group B). One patient in each group had a positive [(13)C]-UBT - 3.84% in Group A and 2.56% in Group B (non-significant difference, NS). The mean annual H. pylori recurrence rate was calculated to be 0.55% and 0.37% in Group A and Group B patients, respectively (NS).

Conclusion: Our results shown a very low re-infection or new infection rates in Israeli adults and are in line with other trials in developed countries; they do not support the a retesting program for patients after a successful eradication therapy.

PubMed Disclaimer

Comment in

Similar articles

Cited by

References

    1. Aliment Pharmacol Ther. 1995;9 Suppl 2:45-51 - PubMed
    1. Eur J Gastroenterol Hepatol. 2002 Aug;14(8):865-71 - PubMed
    1. J Infect Dis. 1997 Jul;176(1):196-200 - PubMed
    1. Am J Gastroenterol. 2005 Sep;100(9):2083-99 - PubMed
    1. J Gastroenterol Hepatol. 1998 Jun;13(6):555-9 - PubMed

MeSH terms

LinkOut - more resources